2-(1H-benzimidazol-2-ylsulfanyl)-N'-[(E)-(4-methoxyphenyl)methylidene]acetohydrazide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(1H-benzimidazol-2-ylsulfanyl)-N'-[(E)-(4-methoxyphenyl)methylidene]acetohydrazide
• 英文别名: 2-(1H-benzimidazol-2-ylsulfanyl)-N-[(E)-(4-methoxyphenyl)methylideneamino]acetamide
• 化学式: C₁₇H₁₆N₄O₂S
• 分子量: 340.4
• InChiKey: DHJZAXSEIXJAEQ-VCHYOVAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(苯并咪唑基硫代)乙酸 肼 、 4-甲氧基苯甲醛 以65%的产率得到
  参考文献：
  名称：

  RUTAVICHYUS A. J.; VALYULENE S. P., TR. AN LITSSR,(1986) N 4/155, 61-68

  摘要：

  DOI：

文献信息

• Intravenous formulation and LC/MS/MS analysis method for GMC1
  申请人：Cox Marc

  公开号：US10010534B2

  公开（公告）日：2018-07-03

  Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.

  某些实施方案涉及一种 GMC1 助溶剂制剂。本文所述的 GMC1 助溶剂制剂可用于治疗前列腺癌、良性前列腺肥大和其他涉及雄激素、糖皮质激素和孕酮受体的激素相关疾病。
• Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
  申请人：Cox Marc

  公开号：US10322113B2

  公开（公告）日：2019-06-18

  Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.

  本发明的实施方案包括调节激素受体活性的方法和组合物。
• RUTAVICHYUS A. J.; VALYULENE S. P., TR. AN LITSSR,(1986) N 4/155, 61-68
  作者：RUTAVICHYUS A. J.、 VALYULENE S. P.

  DOI：——

  日期：——
• ADENYLYL CYCLASES AS NOVEL TARGETS FOR THE TREATMENT OF INFECTION BY EUKARYOTIC PATHOGENS
  申请人：Levin Lonny

  公开号：US20100063099A1

  公开（公告）日：2010-03-11

  The present invention relates to a method of preventing or treating a disease caused by infection by a eukaryotic pathogen, wherein the method comprises administering an effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of a eukaryotic pathogen's adenylyl cyclase that do not substantially modulate an adenylyl cyclase of the subject. The invention also provides methods for culturing eukaryotic pathogens and methods for inducing the pathogenic state in vitro.
• ADENYLYL CYCLASES AS NOVEL TARGETS FOR ANTIBACTRIAL INTERVENTIONS
  申请人：Levin Lonny

  公开号：US20100168203A1

  公开（公告）日：2010-07-01

  The present invention relates to a method of preventing or treating a disease caused by bacterial infection by administering an effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of bacterial adenylyl cyclase that do not substantially modulate adenylyl cyclase of the subject. The invention also provides methods for culturing bacterial pathogens and methods for inducing the pathogenic state in vitro.